Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 558 for:    G MInor
Previous Study | Return to List | Next Study

Genomics in Michigan Impacting Observation or Radiation (G-MINOR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02783950
Recruitment Status : Active, not recruiting
First Posted : May 26, 2016
Results First Posted : February 25, 2021
Last Update Posted : February 25, 2021
Sponsor:
Collaborators:
Michigan Urological Surgery Improvement Collaborative (MUSIC)
GenomeDx Biosciences Corp
Information provided by (Responsible Party):
University of Michigan Rogel Cancer Center

Brief Summary:
To determine the impact of Decipher test results on adjuvant treatment decisions of high-risk post-RP patients with undetectable post-op prostate specific antigen (PSA) compared to clinical factors alone.

Condition or disease Intervention/treatment Phase
Prostate Cancer Other: Decipher Prostate Cancer Classifier Not Applicable

Detailed Description:
This prospective, randomized trial will compare the receipt of adjuvant therapy for high-risk radical prostatectomy (RP) patients who undergo Decipher testing to those who do not. 350 subjects from within the statewide Michigan Urological Surgery Improvement Collaborative (MUSIC) will be randomized to either a Genomic Classifier (Decipher) or Usual-Care-Based (UC) strategy for a period of three months. If enrolled during the Genomic Classifier period, both subjects and their treating physician will be provided Decipher results and CAPRA-S scores. In the UC periods, CAPRA-S scores but not Decipher results will be provided.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 356 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Genomics in Michigan Impacting Observation or Radiation (G-MINOR)
Actual Study Start Date : January 17, 2017
Actual Primary Completion Date : January 2020
Estimated Study Completion Date : August 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Arm Intervention/treatment
GC (Decipher) Arm
If enrolled during the Genomic Classifier (GC) period, both subjects and their treating physician will be provided GC (Decipher Prostate Cancer Classifier from GenomeDx) and CAPRA-S scores following prostatectomy.
Other: Decipher Prostate Cancer Classifier
The Decipher test (GenomeDx Biosciences, San Diego, CA) is a genomic test that predicts high grade disease, the probability of metastasis and prostate cancer-specific mortality for men with prostate cancer.
Other Name: Decipher Post-Op

No Intervention: Usual-Care-Based (UC) Arm
If enrolled during the UC period, only the CAPRA-S results will be provided.



Primary Outcome Measures :
  1. Number of Participants That Receive Adjuvant Therapy (Radiation and/or Hormone Therapy) [ Time Frame: within 18 months of radical prostatectomy ]
    Adjuvant will be defined as preceding biochemical recurrence (BCR) (i.e.: PSA ≥ 0.2 ng/ml) and within 18 months of radical prostatectomy.


Secondary Outcome Measures :
  1. Time (From Randomization) to Adjuvant Treatment Administration [ Time Frame: Up to 18 months post randomization ]
    Adjuvant treatment (radiation and/or hormone) is defined as preceding BCR. BCR occurs when prostate specific antigen (PSA) ≥ 0.2 ng/ml.

  2. Time (From Randomization) to Salvage Treatment Administration [ Time Frame: Up to 5 years post randomization ]
    Salvage treatment (radiation and/or hormone therapy) is defined as either after BCR or >18 months after surgery in the absence of documented BCR

  3. Time (From Randomization) to Biochemical Recurrence (BCR) [ Time Frame: Up to 5 years post randomization ]
    BCR is defined as PSA ≥ 0.2 ng/ml.

  4. Time (From Randomization) to Metastatic Disease (Regional or Distant) [ Time Frame: Up to 5 years post randomization ]
    Metastasis is determined based on CT, MRI, bone scan, and/or positron emission tomography (PET) scan

  5. Michigan Urological Surgery Improvement Collaborative (MUSIC) Patient Reported Outcomes (PRO) [ Time Frame: Up to 24 months post radical prostatectomy ]
    Composite Expanded Prostate Cancer Index Composite (EPIC)-26 domain scores for a) urinary irritative function, b) urinary incontinence, and c) sexual function will be measured at baseline and 24 months post-radical prostatectomy. Each of the 3 domains is scaled from 0-100 (higher is better).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Prostate cancer patients who have undergone radical prostatectomy
  • PSA < 0.1 ng/ml at enrollment
  • At least one of the following:

    • pT3 (seminal vesicle invasion or extraprostatic extension), or
    • Positive surgical margins
  • Radical prostatectomy within one year of enrollment

Exclusion Criteria:

  • Individuals who have any of the following will not be eligible to participate:

    • Have regional or distant metastatic disease
    • Received any radiation or hormone therapy (neo-adjuvant, adjuvant, or salvage)
    • Node positive

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02783950


Locations
Layout table for location information
United States, Michigan
University of Michigan Hospital and Health Systems
Ann Arbor, Michigan, United States, 48109
Sponsors and Collaborators
University of Michigan Rogel Cancer Center
Michigan Urological Surgery Improvement Collaborative (MUSIC)
GenomeDx Biosciences Corp
Investigators
Layout table for investigator information
Principal Investigator: Todd Morgan, MD University of Michigan
Principal Investigator: Michael Cher, MD Wayne State University
  Study Documents (Full-Text)

Documents provided by University of Michigan Rogel Cancer Center:
Additional Information:
Publications:
Buja, A., Hastie, T. J. and Tibshirani, R. J. (1989). Linear smoothers and additive models (with discussion). Annals of Statistics, 17, 453-555.
Campbell, Michael J., and Stephen J. Walters. How to Design, Analyse and Report Cluster Randomised Trials in Medicine and Health Related Research. John Wiley & Sons, 2014.

Layout table for additonal information
Responsible Party: University of Michigan Rogel Cancer Center
ClinicalTrials.gov Identifier: NCT02783950    
Other Study ID Numbers: UMCC 2016.020
CU 008 ( Other Identifier: GenomeDx Biosciences Corp )
HUM00110858 ( Other Identifier: University of Michigan )
First Posted: May 26, 2016    Key Record Dates
Results First Posted: February 25, 2021
Last Update Posted: February 25, 2021
Last Verified: February 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University of Michigan Rogel Cancer Center:
Genomics
Adjuvant Treatment
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Prostatic Diseases